SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs unusually large ASH conference booth is fueling speculation about REGAL trial results, a partnership, or a buyout, alongside discussion of the delayed 80th trial event and final data. Bulls interpret the booth and quiet period as signs of positive developments or pharma interest, while skeptics caution that neither the booth nor acquisition rumors confirm a deal or trial success.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs sharp selloff is being linked to SemiAnalysis criticism of reliability at its legacy Canadian sites and concerns about executing and funding its AI data-center buildout, alongside weakness across neocloud stocks. Traders dispute the criticism as misleading and debate whether the shares are oversold; separate Anthropic-deal chatter remains unconfirmed.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being linked to the launch of confidential perpetual trading powered by Hyperliquid, which traders see as strengthening its privacy-focused appeal. The community is also emphasizing NEARs AI-agent ambitions and broader altcoin momentum, though some traders question whether the move is driven by fundamentals or speculative buying.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa is the main focus, with traders watching for FDA acceptance and possible priority review; the filing has drawn a muted share-price reaction. Debate over the drugs prospects and commercial potentialalongside concerns about clinical results, competition, managements go-it-alone strategy and the prolonged sellofftempers bullish views.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks pivot toward AI data centers, highlighted by a long-term Meta lease and substantial secured-debt financing, dominates discussion. Bulls see a path to contracted revenue beyond Bitcoin mining, while skeptics question the debt burden, execution timeline, and why the shares have remained weak despite the deal and Bitcoin strength.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

Traders are focused on ASMLs upcoming Q3 report, especially guidance and demand signals as the company no longer publishes quarterly bookings; some are parsing its annual and quarterly sales outlook to gauge the implied Q4 pace. The community sees the results as an important read-through for AI and semiconductor-equipment demand, while weighing earnings-related volatility and the risk of a muted reaction.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Speculation around a suspected pneumonic-plague incident at a Russian research institute has renewed discussion of biodefense demand for Emergents medical countermeasures, alongside hopes for congressional action on PAHPA and future government contracts. Traders are divided between seeing the news as a potential catalyst and warning that the plague reports remain unverified; short-squeeze claims are speculative.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Speculation that Johnson & Johnson could acquire Sellas Life Sciences is a dominant topic, with traders citing J&Js oncology ambitions and alleged executive connections as clues; no deal is confirmed, and some posters caution against reading too much into them. J&Js upcoming quarterly report is also drawing attention.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is drawing attention ahead of its Q3 earnings report, which kicks off major-bank reporting season. Traders are positioning for a possible earnings-driven move while debating the bank-sector pullback and the effects of higher yields on margins and credit conditions.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is at the center of a debate over the S&P 500s outlook: many investors favor steady, long-term accumulation, while others warn of a correction amid elevated rates, inflation and oil prices, geopolitical uncertainty, and concerns about AI-led valuations. No single VOO-specific catalyst dominates the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BOTS, Inc. is a global technology company. The firm focuses on on robotics, Blockchain-based solutions including decentralized finance applications, cybersecurity, crypto generation, mining, equipment repair, and extended warranties on Bitcoin mining equipment. It also owns a portfolio of digital assets and crypto-related businesses such as BeadSwap, a decentralized crypto exchange, Bitcoin ATM machines, and corresponding U.S. patents. The company was founded on December 30, 2010 and is headquartered in San Juan, Puerto Rico.

BOTS Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

BTZI News